Table 4 Surgical remission rates in patients with macroadenoma according to preoperative SSA therapy duration
SSAs ≤6 months (n = 49) | SSAs >6 months (n = 18) | P | |
|---|---|---|---|
Mean basal GH at diagnosis (μg/L) | 46.11 ± 16.40 | 35.96 ± 14.69 | 0.383 |
Mean IGF-1 at diagnosis (μg/L) | 874.9 ± 309.7 | 789.3 ± 257.1 | 0.702 |
Mean SSAs therapy duration (month) | 3.6 ± 0.98 | 18.1 ± 11.0 | <0.001 |
Remission rate for GH | 25/49 (51.0) | 13/18 (72.2) | 0.121 |
Knosp grade 0 (%) | 10/15 (66.7) | 5/6 (83.3) | 0.623 |
Knosp grade 1–3 (%) | 15/28 (53.6) | 7/11 (63.6) | 0.725 |
Knosp grade 4 (%) | 0/6 (0) | 1/1 (100) | 0.143 |
Remission rate for IGF-1 | 14/47 (29.8) | 11/18 (61.1) | 0.020 |
Knosp grade 0 (%) | 4/15 (26.7) | 4/6 (66.7) | 0.146 |
Knosp grade 1–3 (%) | 10/26 (38.5) | 6/11 (54.5) | 0.018 |
Knosp grade 4 (%) | 0/6 (0) | 1/1 (100) | 0.143 |